Log In
BCIQ
Print this Print this
 

TK216

Also known as: TK-216

  Manage Alerts
Collapse Summary General Information
Company Oncternal Therapeutics Inc.
DescriptionSmall molecule ets-family transcription factor inhibitor that targets a fusion protein comprising Ewing sarcoma breakpoint region 1 (EWSR1; EWS) and Friend leukemia virus integration 1 (FLI1)
Molecular Target Ewing sarcoma breakpoint region 1 (EWSR1) (EWS) ; Friend leukemia virus integration 1 (FLI1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSarcoma
Indication DetailsTreat Ewing's sarcoma; Treat relapsed or refractory Ewing's sarcoma
Regulatory Designation U.S. - Fast Track (Treat relapsed or refractory Ewing's sarcoma);
U.S. - Orphan Drug (Treat Ewing's sarcoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today